18 June 2013
Keywords: CNS drugs, Development time, Regulatory approval, Tufts CSDD
Article | 06 March 2012
Drugs developed to treat central nervous system (CNS) diseases take 35% longer to complete clinical trials and receive regulatory approval compared ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 March 2012
17 June 2013
© 2013 thepharmaletter.com